# DESCRIPTION

## FIELD OF THE INVENTION

- relate to substances for insulin secretion stimulation

## BACKGROUND OF THE INVENTION

- introduce insulin secretion mechanism
- describe cholinergic parasympathetic stimulation
- explain incretin effect
- discuss post absorptive phase
- describe pancreas innervation
- explain insulin secretion insufficiency
- discuss diabetes mellitus types
- describe current treatments for diabetes
- highlight need for new treatments
- introduce Nogo-A protein

## SUMMARY OF THE INVENTION

- describe Nogo-A knockout mice experiment
- summarize increased insulin secretion result
- propose Nogo-A antagonist for blood glucose control
- propose use of Nogo-A antagonist for insulin secretion deficiency
- describe method of controlling blood glucose levels
- describe method of preventing insulin secretion deficiency
- propose pharmaceutical formulation with co-agent

## DETAILED DESCRIPTION

- define insulin secretion deficiency
- define Nogo-A
- describe Nogo-A polypeptide
- describe Nogo-A fragments
- describe Nogo-A antagonists
- describe Nogo-A antibody
- describe monoclonal antibody
- describe humanised antibody
- describe donor antibody
- describe acceptor antibody
- describe CDRs
- describe anti-Nogo-A antibody
- describe humanised anti-Nogo-A antibody
- describe siRNA
- describe peptidomimetic
- describe Nogo-A protein production
- describe expression systems
- describe pharmaceutically acceptable carrier
- describe treatment
- describe subject
- describe efficacy
- describe insulin secretory effective amount
- describe antibody response
- describe neutralising anti-Nogo-A antibody
- describe humanised variants of mAbs
- describe siRNA with Nogo-A antagonizing activities
- describe autoantibodies
- describe immunogens
- describe epitopes of Nogo-A
- describe immunization/booster protocols
- describe therapeutic levels of circulating neutralising anti-NogoA autoantibodies
- describe precedent for immunization against endogenous fertility hormones
- describe composition comprising a Nogo-A polypeptide or fragment thereof

### Nogo-A Antagonists

- describe Nogo-A antagonists
- describe neutralising anti-Nogo-A antibody
- describe humanised variants of mAbs
- describe siRNA with Nogo-A antagonizing activities

### Compositions

- provide Nogo-A antagonists
- provide pharmaceutical compositions
- describe composition forms
- list pharmaceutically acceptable ingredients
- describe injectable compositions
- describe liquid formulations
- describe dry product reconstitution
- list additives for liquid preparations
- describe depot preparations
- describe solid compositions
- describe inhalation formulations

### Mode of Administration

- describe administration methods

### Combination

- describe combination therapy
- list co-agents for insulin secretion
- describe administration timing
- describe pharmaceutical formulation combinations
- describe neutralising anti-Nogo-A antibody formulations
- describe specific antibody variants

### Patients

- describe patient populations

## USE ACCORDING TO THE INVENTION

- provide use of Nogo-A antagonist
- provide use of Nogo-A antagonist for insulin secretion deficiency
- provide use of Nogo-A antagonist for diabetes mellitus
- provide use of Nogo-A antagonist for type II diabetes
- provide method for controlling blood glucose levels
- provide use of Nogo-A polypeptide for controlling blood glucose levels
- provide method for controlling blood glucose levels using Nogo-A polypeptide
- specify subject conditions for use or method
- specify Nogo-A antagonist types

## EXAMPLES

- define abbreviations

### Example 1

- investigate Nogo-A expression in pancreas and islets
- describe Nogo-A KO mice generation
- perform RT-PCR on brain, sciatic nerve, pancreas, and isolated islets
- analyze Nogo-A expression in β-cells and neuronal cells
- summarize results on Nogo-A expression

### Example 2

- study insulin secretion profile in Nogo-A KO mice
- measure blood glucose and insulin release
- perform intraperitoneal glucose tolerance tests
- analyze insulin secretion after glucose injection
- measure insulin sensitivity
- study in vivo stimulation of β-cell secretion
- perform intravenous glucose tolerance tests
- analyze insulin secretion after carbachol injection
- measure insulin content per β-cell
- study parasympathetic input and β-cell sensitivity
- investigate vagally-stimulated insulin secretion
- measure plasma pancreatic polypeptide levels
- analyze gluco-incretin input
- measure plasma GIP and GLP-1 levels
- perform in vivo insulin secretion assays
- describe intraperitoneal glucose tolerance tests
- describe intravenous glucose tolerance tests
- describe insulin tolerance tests
- describe vagally stimulated islet hormone secretion
- summarize results on insulin secretion and parasympathetic input

### Example 3

- study in vitro sensitivity of β-cells to insulin secretagogues
- perform in vitro insulin secretion assays
- analyze insulin secretion in response to carbachol and GLP-1
- summarize results on in vitro insulin secretion
- discuss therapeutic potential of Nogo-A inhibition

### Example 4

- introduce Nogo-A antagonist
- describe treatment of diabetic db/db animals
- compare insulinemia of treated and control groups
- describe challenges in vivo
- compare plasma insulin levels and pancreatic insulin content
- assess glucose-induced insulin secretion
- investigate insulin secretion capacity
- measure parasympathetic tone
- study β-cell responsiveness to secretagogues
- summarize results of Nogo-A neutralization
- describe db/db homozygous mice

### Statistical Analysis.

- describe statistical analysis method

